Contribution of androgens to chronic allograft nephropathy is mediated by dihydrotestosterone  by Antus, Balazs et al.
Kidney International, Vol. 60 (2001), pp. 1955–1963
Contribution of androgens to chronic allograft nephropathy is
mediated by dihydrotestosterone
BALAZS ANTUS, YOUSHENG YAO, SHANYING LIU, ERWEI SONG, JENS LUTZ, and UWE HEEMANN
Department of Nephrology, University Hospital Essen, Essen, Germany, and Semmelweis Medical University, Budapest, Hungary
Contribution of androgens to chronic allograft nephropathy is process [2, 3]. Consistent with this concept, donor and
mediated by dihydrotestosterone. recipient gender may influence renal transplantation. In
Background. Donor and recipient gender influence long-term general, graft survival is enhanced in female recipientsallograft outcome after kidney transplantation. Sex hormones
while kidneys from male donors have better long-termare likely to contribute to these gender-related differences. The
present study investigated the role of androgens and their inhi- allograft outcome [4].
bition on the development of chronic allograft nephropathy. For many years, it has been hypothesized that the im-
Methods. Male or female Fisher (F344) kidneys were ortho- pact of donor gender on graft survival may primarily resulttopically transplanted into intact male Lewis recipients. Ani-
from genetically determined differences in allograft sizemals were treated either with testosterone, the antiandrogen
flutamide, the 5-reductase inhibitor finasteride, or vehicle. and structure, as females have smaller kidneys than
Twenty weeks after transplantation animals were harvested males. Therefore, transplantation of a female kidney into
for histology, immunohistology, and molecular analysis. a male recipient may be functionally inadequate for theResults. Testosterone treatment resulted in an increased pro-
demands of the recipient, which results in hyperfiltration-teinuria as well as profound glomerulosclerosis, tubulointersti-
induced glomerular injury and may thus be responsibletial fibrosis, and mononuclear cell infiltration that paralleled
enhanced intragraft mRNA levels of transforming growth fac- for the reduced allograft survival of female donors [5, 6].
tor- (TGF-) and platelet-derived growth factor-A and -B On the other hand, gender-related differences among
chain (PDGF-A and -B). In contrast, flutamide and finasteride
renal transplant recipients may be attributed to sex hor-reduced glomerulosclerosis as well as the inflammatory cell
mones. Sex hormones influence renal hemodynamics,infiltration associated with decreased TGF-, PDGF-A, and -B
chain mRNA expression. No gender-related donor differences mesangial cell proliferation, extracellular matrix metab-
were noted between the groups. olism, as well as synthesis and release of vasoactive agents,
Conclusions. Our data suggest that dihydrotestosterone me-
cytokines, and other growth factors, which in turn arediates the adverse effects of androgens on chronic allograft
capable of altering the progression of renal diseases [7].nephropathy. The inhibition of androgens improves long-term
allograft outcome after kidney transplantation. In males, the presence of the major androgen hormone
testosterone is widely believed to promote renal injury
in several non-transplant animal models of glomerulo-
Chronic allograft nephropathy is the most important sclerosis [8–10]. In addition, various humoral and cellular
cause of late graft loss after kidney transplantation. It immune responses are regulated by sex hormones [11].
is characterized by a progressive deterioration of renal Utilizing ovariectomized female recipients, we re-
function associated with nonspecific histopathological cently demonstrated that in the absence of the main sex
findings such as glomerulosclerosis, tubular atrophy, in- hormones, kidneys derived from female donors deterio-
terstitial fibrosis, inflammatory cellular infiltration, and rate more rapidly than allografts of male origin [12]. Our
intimal thickening of graft arteries [11]. data indicated that testosterone substitution exacerbates
Apart from alloantigen-dependent mechanisms, allo- chronic allograft nephropathy in kidneys of male origin.
antigen-independent factors are involved in the rejection There remained a number of open questions: Do these
results apply to grafts of male origin only? Does testoste-
rone also tamper renal function in intact males? Finally,Key words: transplantation, donor gender, sex hormone, testosterone,
late graft loss, glomerulosclerosis, tubular atrophy. does therapeutic interference with testosterone receptors
prevent allograft damage? Are those growth factors that
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The present study was undertaken to answer these ques- action, we employed the 5-reductase inhibitor finaster-
ide to control for effects not mediated by testosteronetions.
itself. 5-Reductase converts testosterone to the more
potent androgenic steroid dihydrotestosterone.
METHODS
Animals Functional measurements
Every four weeks, body weight was measured and 24-Naive inbred rats (Charles River, Sulzfeld, Germany),
weighing 200 to 250 g, were used throughout the experi- hour urine samples were collected using metabolic cages
with a urine-cooling system. Quantitative urine proteinments: male and female Fisher (F344, RT1v1) rats served
as donors, whereas male Lewis (Lew, RT1) rats were was nephelometrically determined. Serum and urine cre-
atinine levels as well as hormones were measured andused as recipients. Animals were kept under standard
conditions and were fed rat chow and water ad libitum. creatinine clearance was calculated at the end of the
study.All experiments were approved by a governmental com-
mittee on animal welfare. After 20 weeks, rats were anesthetized with diethyl-
ether, and immediately thereafter, intra-aortic blood
Renal transplantation pressure was measured (Sirecust 404, Siemens, Dort-
mund, Germany). Animals then were bled and the trans-Under ketamine (Ketamin, 100 mg/kg IP; CP-Pharma,
Burgdorf, Germany) and xylacine (Rompun, 10 mg/kg planted kidney was removed. Samples were snap frozen
in liquid nitrogen for immunohistological staining andIP; Bayer, Leverkusen, Germany) anesthesia, the left
donor kidney was removed, cooled, and positioned or- molecular analysis or fixed in formalin for light micro-
scopical evaluation.thotopically into the recipient. Donor and recipient renal
artery, vein, and ureter were anastomosed end to end
Histology and immunohistologywith 10-0 Prolene sutures. No ureteral stent was used. To
overcome infectious complications caused by operation, For histology, kidney tissues were fixed in 4% buffered
formalin, embedded in paraffin, and stained with eitherrats received Cephtriaxone (Rocephin; 20 mg/kg/day,
intramuscularly; Hoffmann-la Roche AG, Grenzach- hematoxylin/eosin or periodic acid-Schiff (PAS). Glomer-
ulosclerosis was defined as a collapse of capillaries, adhe-Wyhlen, Germany) on the first postoperative day. Ani-
mals were treated with low-dose cyclosporine A (1.5 mg/ sion of the obsolescent segment of Bowman’s capsule
and entrapment of hyaline in the mesangium [13]. Atkg/day SC; Novartis GmbH, Nu¨rnberg, Germany) over
the first ten days after transplantation to overcome an least 200 glomeruli were counted per kidney section and
the proportion of sclerosed to total glomeruli was ex-initial episode of acute rejection. The contralateral native
kidney was removed on the tenth postoperative day. pressed as a percentage (glomerulosclerosis index). Glom-
erulopathy, tubular atrophy, interstitial fibrosis and vas-
Experimental design cular intimal proliferation were quantified according to
the Banff 1997 classification [14] and scored 0 to 3, re-Intact male recipients were transplanted either with a
male or a female kidney. Animals were assigned to the spectively.
For immunohistology, cryostat sections (4 m) werefollowing eight experimental groups (N  6 per group)
according to donor gender and treatment: male graft, fixed in acetone, air dried, and individually stained with
primary monoclonal mouse-derived antibodies againsttestosterone treatment (M/T); male graft, vehicle treat-
ment (M/V); male graft, flutamide treatment (M/FL); monocytes/macrophages (ED1) and CD5 T-lympho-
cytes (OX19; Serotec Camon Labor-Service GmbH, Wies-male graft and finasteride treatment (M/FI); female graft,
testosterone treatment (F/T); female graft, vehicle treat- baden, Germany). After incubation with primary anti-
body, sections were incubated with rabbit anti-mousement (F/V); female graft, flutamide treatment (F/FL);
and female graft and finasteride treatment (F/FI). Tes- IgG and thereafter with the alkaline phosphatase antialka-
line phosphatase (APAAP) complex (Dako A/S, Ham-tosterone (0.5 mg/kg), testosterone receptor blocker flu-
tamide (25 mg/kg), and 5-reductase inhibitor finasteride burg, Germany). Cells staining positive were counted
and expressed as cells per field of view (cells/fv). At least(25 mg/kg) were dissolved in sesame oil and subcutane-
ously administered every second day (0.1 mL) following 20 fields of view per section and per specimen were
evaluated at 400 magnification.transplantation until harvesting. Control animals were
given sesame oil alone.
RNase protection assayGrafts of male and female gender were used to control
for the effects of donor gender. The testosterone recep- Total RNA was extracted from the kidney tissues ac-
cording to the modified guanidine-isothiocyanate prepa-tor antagonist flutamide was applied to block the effects
of testosterone at the receptor site. Since testosterone ration [15] and stored at 80C until further processing.
Intragraft mRNA expression specific for transformingis not the active form of the hormone at many sites of
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growth factor-1 (TGF-1) and glyceraldehyde-3-phos- given as the ratio of intensity of growth factors to -actin
phate dehydrogenase (GAPDH) was determined by mRNA.
RNase protection assay with the use of in vitro tran-
Statistical analysisscription and RPA Kit (Pharmingen, Becton Dickinson
GmbH, Hamburg, Germany) according to the protocol Data are presented as mean 	 SEM. Parametric data
provided by the manufacturer. Briefly, antisense RNA were compared using one-way analysis of variance, fol-
probes were prepared with the use of T7 RNA polymerase lowed by a multiple pair-wise comparison according to
transcription in the presence of [32P]UTP. Radiolabeled the Newman-Keuls test. Nonparametric data were tested
RNA probes were then extracted with Tris-saturated using the Kruskal-Wallis one-way analysis of ranks. A
phenol and chloroform:isoamyl alcohol and precipitated P value of less than 0.05 was considered significant.
with ethanol. Probe activity was measured in a scintilla-
tion counter. Thereafter, 10 g total RNA from each
RESULTSsamples were hybridized together with a specific radio-
labeled antisense probe (activity 
3  105 cpm) at 56C Functional data
overnight. After purification and precipitation, protected Proteinuria did not differ significantly between vehi-
fragments were separated by electrophoresis on a 5% cle-treated animals (M/V, F/V) according to the origin
polyacrylamide gel. Intensities of the protected bands of the kidney by week 20 (Fig. 1). In contrast, animals
were quantified by a phosphorimaging analyzer (Fuji- treated with testosterone had developed an increased
BAS 1500, Du¨sseldorf, Germany), and the ratios of the urinary protein excretion. The level of protein excretion
investigated genes to GAPDH (internal control) were was comparable throughout the period observed be-
calculated. tween flutamide-, finasteride-, and vehicle-treated rats
independent of donor gender.Reverse transcriptase-polymerase chain reaction
Serum creatinine levels, creatinine clearance, hemato-
Isolated RNA was amplified by reverse transcription crit, and mean arterial blood pressure did not signifi-
(RT) with an Oligo(dT)12–18 primer (GIBCO/BRL, Karls- cantly differ between the groups (Table 1). However,
ruhe, Germany). One microgram of total RNA was there was a tendency towards an increased blood pres-
added to 0.5 g of primer. A reaction mixture containing
sure in animals that had received a female kidney as
the RT buffer solution [(GIBCO/BRL); adenosine, thy-
compared with those with a graft of male origin.
midine, guanosine, and cytosine triphosphate each in a
With respect to sex hormones, there was a trend to-concentration of 0.2 mmol/L/L (Boehringer Mannheim
wards increased serum testosterone levels in testoster-GmbH, Mannheim, Germany); 0.5 L of 40 U/L of
one- and flutamide-treated animals as compared withrecombinant ribonuclease inhibitor (Promega) and 0.5 L
vehicle-treated rats. Finasteride did not significantly in-of 200 U/L M-MLV reverse transcriptase (GIBCO/
fluence these levels.BRL)] was added and the first chain reaction allowed
At the beginning as well as during follow-up, bodyto proceed (42C, 1 hour). The reaction was halted by
weights were comparable in all groups (Table 2). Simi-heating to 95C for five minutes followed by cooling on
larly, the change in body weight between transplantationice.
and harvesting did not differ among the groups. At theSpecific cDNA products corresponding to mRNA for
time of transplantation, the donor kidney weight/recipi-the PDGF-A chain [16], PDGF-B chain [17], and -actin
ent body weight ratio (kw/bw) was lower in recipients[18] were amplified using the polymerase chain reaction
of a female kidney as compared with animals with a(PCR). One microliter from RT reaction was taken for
kidney of male origin. However, by the end of the follow-PCR, which was performed in PCR buffer (Qiagen
up period, the kw/bw ratio increased to the same level inGmbM, Hilden, Germany) using 0.2 mmol/L/L of each
all groups irrespective of whether animals had received adeoxynucleoside triphosphates, 1 mol/L/L of both prim-
graft of male or female origin.ers (Eurogentec, Ko¨ln, Germany), and 2.5 U thermus
By week 20, prostate and vesicle were profoundly en-Aquaticus (Taq) DNA polymerase (Dianova). A Perkin-
larged in testosterone-treated animals (M/T and F/T),Elmer Thermal Cycler (Model 9600; Perkin-Elmer, Nor-
whereas flutamide and finasteride resulted in a significantwalk, USA) was used for amplification allowing 30 to
regression of both organs.35 cycles for each primer.
The amplified PCR product was identified by electro-
Histology and immunohistologyphoresis on 1.5% agarose gel stained with ethidium bro-
At the end of the follow-up period, vehicle-treatedmide. Cytokine cDNA was semiquantitated by densito-
animals (M/V, F/V), independent of donor gender, hadmetric comparison with -actin (internal control) from
developed glomerulosclerosis, tubular atrophy, intersti-the same sample after the positive image was digitized
by video for computerized densitometry. The results are tial fibrosis, inflammatory cellular infiltration, and inti-
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Fig. 1. (A) Changes in 24-hour urinary protein excretion during the course of the experiment in animals that had received a kidney of male origin.
Symbols and abbreviations are: () M/T, male graft and testosterone treatment; () M/V, male graft and vehicle treatment; () M/FL, male graft
and flutamide treatment; () M/FI, male graft and finasteride treatment. *P  0.05 vs. vehicle. (B) Changes in 24-hour urinary protein excretion
during the course of the experiment in animals that had received a kidney of female origin. Symbols and abbreviations are: () F/T, female graft
and testosterone treatment; () F/V, female graft and vehicle treatment; () F/FL, female graft and flutamide treatment; () F/FI, female graft
and finasteride treatment. *P  0.05 vs. vehicle.
Table 1. Mean arterial blood pressure and serum constituents at the time of harvesting
Mean arterial Creatinine
blood pressure Creatinine clearance Testosterone
Groups mm Hg mg/dL mL/min/100 g ng/dL
Male graft/testosterone (M/T) 90.8	4.7 0.87	0.03 0.33	0.02 23.5	6.8
Male graft/vehicle (M/V) 89.3	11.9 0.82	0.02 0.35	0.01 12.9	2.9
Male graft/flutamide (M/FL) 97.5	6.3 0.80	0.04 0.34	0.02 18.7	4.1
Male graft/finasteride (M/FI) 82.0	9.9 0.84	0.07 0.36	0.03 12.9	3.1
Female graft/testosterone (F/T) 96.7	9.9 0.86	0.04 0.30	0.03 26.0	4.0
Female graft/vehicle (F/V) 114	5.6 0.74	0.04 0.33	0.02 15.7	6.4
Female graft/flutamide (F/FL) 113	5.4 0.69	0.02 0.34	0.04 31.0	6.4a
Female graft/finasteride (F/FI) 121	6.3 0.71	0.03 0.34	0.02 13.1	2.3
a P  0.05 vs. vehicle treatment in animals with a female graft
mal thickening of graft arteries, as typical signs of chronic ation of vascular smooth muscle cells became increas-
ingly obvious. The deleterious effects of testosterone wereallograft nephropathy (Table 3 and Fig. 2).
Administration of testosterone resulted in a markedly less pronounced in grafts of male (M/T) origin. Although
the glomerulosclerosis index was significantly higherelevated degree of glomerular sclerosis (more than 40%)
in recipients of a female graft (F/T) as compared with than in vehicle-treated animals (M/V), this was accompa-
nied by a moderate accumulation of matrix proteins invehicle-treated animals with a kidney of the same origin
(F/V). Furthermore, testosterone-treated animals devel- the tubulointerstitium and a slightly elevated degree of
intimal proliferation in graft arteries as compared withoped a significantly higher degree of interstitial fibrosis,
and a moderate tubular atrophy was observed in approxi- vehicle treatment (M/V).
The structural changes typically associated with chronicmately 25% of the cortical tubuli. In addition, luminal
obliteration of graft arteries (up to 25%) and the prolifer- allograft nephropathy remained suppressed, almost to
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Table 2. Body weight and donor kidney weight/recipient body weight ratio at the time of the transplantation and harvesting
Seminal Donor kidney weight/
Prostate vesicle Body weight g recipient body weight
Groups N g Transplantation Harvesting Transplantation Harvesting
Male graft/testosterone (M/T) 8 0.84 0.89 240	9.1 409	4.9 0.0032 0.0038
Male graft/vehicle (M/V) 7 0.75 0.79 251	5.1 437	6.2 0.0029 0.0035
Male graft/flutamide (M/FL) 6 0.42a 0.61 269	12.3 415	14.3 0.0028 0.0034
Male graft/finasteride (M/FI) 7 0.33a 0.35a 327	6.7 422	7.2 0.0026 0.0034
Female graft/testosterone (F/T) 7 0.66b 1.09b 280	7.9 398	16.7 0.0021 0.0033
Female graft/vehicle (F/V) 8 0.46 0.72 271	15.2 419	6.6 0.0021 0.0032
Female graft/flutamide (F/FL) 7 0.31b 0.46b 262	13.8 384	16.5 0.0022 0.0034
Female graft/finasteride (F/FI) 6 0.21b 0.26b 280	14.7 418	15.6 0.0019 0.0039
Prostate and seminal vesicle weight were measured at harvesting.
a P  0.05 vs. vehicle treatment in animals with a male graft
b P  0.05 vs. vehicle treatment in animals with a female graft
Fig. 2. Periodic acid-Schiff (PAS) staining demonstrated severe glomerulosclerosis and tubulointerstitial fibrosis in testosterone-treated animals
that had received a kidney of male (A) or female origin (B) as compared with vehicle-treated rats with a male (C ) or female (D) kidney. In
contrast, flutamide-treated recipients of a male (E ) or female (F ) kidney as well as finasteride-treated animals with a graft of male (G) or female
(H ) origin preserved their renal allograft structure.
the same extent, in animals treated with either flutamide Immunohistochemical analysis of graft tissues re-
vealed mononuclear cell infiltration in all groups, localiz-or finasteride as compared with vehicle-treated animals
regardless of donor gender. Accordingly, flutamide and ing preferentially in perivascular and periglomerular ar-
eas (Table 3). However, while testosterone treatmentfinasteride treatment significantly reduced the glomeru-
losclerosis index, which was accompanied by well-pre- increased the number of CD5T lymphocytes and ED1-
positive macrophages, flutamide and finasteride reducedserved tubulointerstitial architecture and no or only mi-
nor intimal thickening of graft arteries. the number of ED1-positive macrophages, particularly
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Groups % 0–12 cells/fv
Male graft/testosterone (M/T) 38.9	7.2a 4.5	0.6 22.4	3.2 21.5	3.4a
Male graft/vehicle (M/V) 25.6	3.8 3.0	0.4 17.6	3.5 13.9	2.8
Male graft/flutamide (M/FL) 9.8	1.1a 1.2	0.5a 18.1	2.6 5.8	0.7a
Male graft/finasteride (M/FI) 10.5	1.8a 1.0	0.4a 9.8	1.1a 7.2	1.1a
Female graft/testosterone (F/T) 42.1	9.3b 6.3	1.2b 25.2	4.7b 19.9	3.9b
Female graft/vehicle (F/V) 25.9	3.1 2.9	0.4 17.3	1.9 12.7	3.0
Female graft/flutamide (F/FL) 11.1	2.2b 1.0	0.2b 16.6	2.8 7.9	1.4
Female graft/finasteride (F/FI) 9.4	3.2b 1.2	0.3b 9.9	1.9b 5.9	1.1b
Glomerulosclerosis, interstitial fibrosis, tubular atrophy and transplant vasculopathy were evaluated according to the Banff 1997 classification.
a P  0.05 vs. vehicle treatment in animals with a male graft
b P  0.05 vs. vehicle treatment in animals with a female graft
in perivascular areas. A similar reduction of infiltrating data by Neugarten et al revealed no difference in humans
CD5 T cells was noted in finasteride, but not in flutam- as well (abstract; Neugarten J et al, J Am Soc Nephrol
ide-treated animals. 11:72A, 2000) [26]. In our study, donor gender did not
influence long-term allograft outcome to a major degree.
Molecular analysis Although a decreased kw/bw ratio in recipients of a graft
The intragraft mRNA expression of growth factor of female origin was noted at the time of transplantation,
TGF-1 and PDGF-A and -B chain paralleled the devel- neither signs of chronic allograft nephropathy nor the
opment of chronic rejection in all groups (Fig. 3 A–C). kw/bw ratio differed between the sexes at the end of the
Accordingly, these levels were most pronounced follow- follow-up. Thus, our data suggest that renal structural
ing testosterone treatment. In contrast, the administra- differences between the sexes are not responsible for
tion of flutamide and finasteride significantly reduced donor gender-related differences: The smaller size of
growth factor levels as compared to vehicle treatment. female grafts may represent a reduced tubular mass that
No donor gender-related differences were noted. The has little influence on long-term allograft outcome. Thus,
mRNA expression for interleukin (IL)-1, IL-2, IL-5, donor gender differences may be attributed to a different
IL-6, IL-10, tumor necrosis factor- (TNF-), and inter- sensitivity of male and female grafts to cyclosporine
feron- (INF-) remained below the limits of detection nephrotoxicity or hormones [27].
in all groups. In contrast to donor gender, modulation of the hor-
monal milieu did have a significant impact on allograft
outcome. We could demonstrate, to our knowledge forDISCUSSION
the first time, that testosterone receptor blockade withAccording to the hyperfiltration hypothesis, once
flutamide ameliorates the development of chronic allo-nephron mass is reduced to a critical level, kidney dam-
graft nephropathy. Another novel finding of our studyage progresses as a result of hypertrophy and subsequent
was that the inhibition of the conversion of testosteronesclerosis of the overworked nephrons [19]. Hyperfiltra-
to dihydrotestosterone with finasteride had similar bene-tion may contribute to the progression of chronic allo-
ficial effects. Therefore, as testosterone and dihydrotes-graft nephropathy, as a number of experimental studies
tosterone are known to bind to the same intracellulardemonstrated that reduced transplanted renal mass ex-
receptor, dihydrotestosterone appears to mediate theaggerates allograft injury, whereas increased functional
adverse effects of androgens on chronic allograft ne-reserve ameliorates this process [20–22].
phropathy. In order to get additional proof for the criticalFor many years, donor gender-related differences in
role of androgens in the rejection, we further evaluatedtransplantation have been explained by the hyperfiltra-
the effects of testosterone. Indeed, exogenous testoster-tion theory. As female kidneys are smaller than males,
one aggravated the rejection process, indicating that theit has been proposed that a mismatch between female
elimination of this detrimental hormonal effect accountsdonor kidney supply, reflected by donor kidney weight,
for the better allograft outcome in antiandrogen-treatedand male recipient functional demands, reflected by re-
animals. These data further suggest that the inferior long-cipient body weight, results in hyperfiltration-induced
term outcome in male recipients observed in clinicalglomerular injury and that this is responsible for the
studies [4] can be explained on the basis of the malereduced survival time of female allografts [5, 6, 23]. How-
hormonal background.ever, several strains of rats show no gender difference
in glomerular numbers [24, 25]. Similarly, preliminary Our results are consistent with the general hypothesis
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Fig. 3. (A) Transforming growth factor-
(TGF-) mRNA expression in renal allografts
20 weeks after transplantation. *P  0.05 vs.
vehicle treatment in animals with a graft of
male origin; §P  0.05 vs. vehicle treatment
in animals with a graft of female origin. (B)
PDGF-A chain mRNA expression in renal
allografts 20 weeks after transplantation. *P
0.05 vs. vehicle treatment in animals with a
graft of male origin; §P 0.05 vs. vehicle treat-
ment in animals with a graft of female origin.
(C) PDGF-B chain mRNA expression in renal
allografts 20 weeks after transplantation. *P
0.05 vs. vehicle treatment in animals with a
graft of male origin; §P 0.05 vs. vehicle treat-
ment in animals with a graft of female origin.
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that androgens promote renal injury. Male laboratory of renal disease. Among these factors, TGF- and PDGF
are generally believed to play an important role in therats of most strains have a higher susceptibility to the
development of proteinuria and glomerulosclerosis, development of chronic allograft nephropathy. TGF-
exerts strong profibrogenic effects, stimulates mesangialwhereas castrated males or female gender seem to be
more resistant for these abnormalities [8–10]. cell proliferation and regulates various inflammatory
processes [37]. Enhanced TGF-1 mRNA and/or proteinIt is well established that high dietary protein intake
exacerbates renal disease [19]. One may speculate that expression has been demonstrated in chronically rejected
kidney allografts in animals [38] as well as in humansthe anabolic effects of testosterone-induced enhanced
protein intake significantly contributed to the develop- [39]. PDGF, on the other hand, consists of a disulfide-
linked dimer of two polypeptides, the PDGF-A andment of allograft injury. However, there was no differ-
ence in body weight between testosterone- and vehicle- PDGF-B chain [40]. It stimulates the proliferation of
mesangial and vascular smooth muscle cells and standstreated animals. Therefore, it is unlikely that an in-
creased protein intake was responsible for the effects of out as one of the most important agents for the promo-
tion of the migration of smooth muscle cells from thetestosterone on the development of allograft lesions.
Testosterone and dihydrotestosterone can have differ- arterial media into the neointima at the site of vascular
rejection [41, 42]. Whether androgens stimulate the syn-ent biological actions. For example, finasteride appears
to be beneficial in the treatment of prostatic hypertrophy thesis of TGF- and/or PDGF in renal tissues is unclear.
However, for example, nonrenal cells such as osteoblasts[28] and male pattern hair loss [29]. In these situations,
dihydrotestosterone rather than testosterone mediates respond to testosterone treatment with elevated produc-
tion of TGF- [43]. In our experiment, the mRNA ex-androgenic effects. Nonsteroidal antiandrogens such as
flutamide exert their antiandrogenic effects by inhibiting pression of TGF-1, PDGF-A and -B chain was pro-
foundly up-regulated in testosterone-treated animals,androgen uptake and/or nuclear binding of androgens
in target tissues [30]. Antiandrogenic compounds are which may have contributed to the more severe injury
in these allografts. In contrast, antiandrogens decreasednow extensively used in the palliative treatment of pa-
tients with advanced prostatic cancer [31]. Furthermore, growth factor mRNA levels in kidneys of both sexes,
and this effect was associated with a better long-termtestosterone—but not dihydrotestosterone—may be in-
volved in the development of increased blood pressure outcome of these grafts.
Finally, several lines of evidence indicate that gonadalin male animal models of hypertension [32, 33]. In our
experiments, testosterone did not increase arterial blood steroid hormones regulate humoral and cellular immune
responses [11]. Testosterone binding sites have been ob-pressure. The reason for this discrepancy is not clear,
but it is conceivable that testosterone exacerbates hyper- served in T cells [44] as well as in macrophages [45].
Furthermore, macrophages possess 5-reductase activitytension in a genetically-defective regulation system, but
not in an intact one. On the other hand, all animals [45]. Thus, direct effects of androgens and their inhibi-
tion on immune cells may have contributed to our results.transplanted with a kidney of female origin developed
a slightly elevated systemic blood pressure by week 20. Androgens seem to have immunosuppressive properties,
as for example, in the regulation of post-traumatic immuno-This mild hypertension may have contributed to the
more pronounced allograft injury observed in female depression [46]. Moreover, some earlier reports indicate
that adult male rats accept allogenic skin grafts for akidneys as compared with males among the testosterone-
treated animals. However, allograft function in female considerably longer period than females [47]. In our ex-
periment, however, graft function was not improved bykidneys derived from flutamide- and finasteride-treated
rats was well preserved despite an elevated blood pres- the proposed immunosuppressive effects of testosterone.
In conclusion, our data suggest that dihydrotestoster-sure. Thus, factors other than hypertension such as the
hormonal milieu seem to be more important in determin- one mediates the adverse effects of androgens on chronic
allograft nephropathy. These androgens, antagonized ei-ing allograft function.
The mechanisms by which androgens contribute to ther by receptor blockade or the inhibition of the conver-
sion of testosterone to dihydrotestosterone, could serverenal allograft injury remain obscure. Testosterone bind-
ing sites have been described in various tissues including as a novel therapeutic approach to prolong kidney graft
survival.the kidney [34]. Furthermore, renal tissues can metabo-
lize testosterone to dihydrotestoterone [35]. Testoster-
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